Rituximab for AAV Linked to Poor Responses to COVID-19 Vaccines

Rituximab for AAV Linked to Poor Responses to COVID-19 Vaccines

315163

Rituximab for AAV Linked to Poor Responses to COVID-19 Vaccines

Treatment with the CD20 inhibitor rituximab is significantly associated with poor antibody responses to COVID-19 vaccines among people with ANCA-associated vasculitis (AAV), a study found. However, the number of antibody-producing B-cells, the rituximab dose, and the timing between last rituximab administration and vaccination were all important factors determining how likely a patient is to develop antibodies following the COVID-19 vaccine. “On the basis of these findings it is reasonable to propose that [antibody-producing B-cell] counts…

You must be logged in to read/download the full post.